NCT03392051View on ClinicalTrials.gov

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

December 28, 2017

Primary Completion Date

March 18, 2018

Study Completion Date

March 18, 2018

Conditions

Elevated Lipoprotein(a)Cardiovascular Diseases

Interventions

DRUG

ISIS 681257

Xmg dose administered as a subcutaneous injection

DRUG

Clopidogrel

75mg tablet administered orally

Trial Locations (1)

H3P 3H5

Clinical Site, Mount Royal

Sponsors

Lead Sponsor

Akcea Therapeutics

All Listed Sponsors

lead

Akcea Therapeutics

INDUSTRY

NCT03392051 - Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel | Biotech Hunter | Biotech Hunter